SecBot SecBot
8-K ·Filed Nov 2, 2026

EBS

Emergent BioSolutions Inc.
BEARISH
Impact 6/10
Horizonweeks Processed14d 10h ago SEC0001367644-26-000110
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The magnitude of the revenue decline (52% YoY) and the second consecutive guidance cut this year signal deteriorating fundamentals beyond the timing-driven MCM lumpiness. Monitor Q4 2026 for the pace of USG contract awards and whether the naloxone decline stabilizes; the CFO transition adds execution risk to the turnaround plan.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

EBS drug pipeline →

ACAM2000

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and marketed since 2007 (smallpox) and 2024 (mpox).
Next catalyst
None dated

What to watchACAM2000 is an approved, revenue-generating product with no pending FDA binary catalyst. Watch for U.S. government contract option exercises (the 10-year ASPR deal has annual renewals) and further international approvals, which drive lumpy quarterly revenue. The Q3 2026 revenue miss and lowered guidance are the near-term headwind to watch.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$6.25
T+0 close · Nov 2, 2026 · via day close
Latest settled
−3.20%
T+5 · $6.05 · next T+20 in 15d
Vs SPY
−2.61%
α at T+5
Latest observation
−4.92%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $6.25entry
  2. T+1 · 13d ago −5.60%α −7.25% · $5.90
  3. T+5 · 7d ago −3.20%α −2.61% · $6.05
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Emergent BioSolutions reported Q3 2026 total revenue of $110.0M, down 52% YoY from $231.1M, and a GAAP net loss of $32.7M versus net income of $51.2M in Q3 2025. Revenue was within the company's prior guidance range but missed the consensus estimate of $123.2M. The company lowered its full-year 2026 revenue guidance to $600M-$645M from $645M-$675M and its adjusted EBITDA guidance to $110M-$140M from $130M-$150M, citing timing of USG and international MCM sales and a 20%-25% YoY decline in commercial (naloxone) revenues.

Key Financial Metrics

EPS (Adj.)
−$0.36
est −$0.39 · +7.7% · GAAP: $-0.64
Revenue
$110.0M
est $123.2M · -10.7% · -52.4% YoY
Rating
in line
Guidance
$600M-$645M
lowered
Free Cash Flow
$114.6M
Gross Margin
14%

Key Facts

  • Q3 2026 total revenue of $110.0M, down 52% YoY from $231.1M, missing consensus of $123.2M
  • GAAP net loss of $32.7M vs net income of $51.2M in Q3 2025; GAAP diluted EPS of ($0.64) vs $0.91
  • Adjusted net loss of $18.7M vs adjusted net income of $65.2M in Q3 2025
  • Adjusted EBITDA of ($4.6M) vs $92.6M in Q3 2025; adjusted EBITDA margin of (4)% vs 40%
  • Full-year 2026 revenue guidance lowered to $600M-$645M from $645M-$675M
  • Full-year 2026 adjusted EBITDA guidance lowered to $110M-$140M from $130M-$150M
  • Naloxone revenue fell 42% YoY to $43.5M; Smallpox MCM revenue fell 68% YoY to $26.7M; Other Products (BAT) fell 87% YoY to $7.6M
  • CFO Rich Lindahl announced retirement effective Dec 31, 2026; Frank Vargo to serve as interim CFO
  • Completed repurchase of $75M aggregate principal of Senior Unsecured Notes in Q3
  • Implemented restructuring in August 2026; incurred $8M of restructuring costs in Q3

Financial Impact

Revenue miss of ~$13.2M vs consensus; full-year revenue guidance cut by $45M at midpoint; adjusted EBITDA guidance cut by $30M at midpoint; Q3 adjusted EBITDA swung from +$92.6M to -$4.6M YoY

revenuenet incomeadjusted EBITDAadjusted gross marginguidance

Segment Breakdown

SegmentRevenueGrowth
Commercial Products (Naloxone)$43.5M-42.0%
MCM Products$59.4M-58.0%

Risk Factors

  • Continued erosion of naloxone revenue due to generic competition and unfavorable price/volume mix
  • Lumpy USG and international MCM procurement timing creates unpredictable quarterly revenue swings
  • CFO retirement and interim CFO appointment introduces leadership uncertainty during restructuring
  • Full-year net loss forecast of $(255M)-$(225M) reflects $191M non-cash impairment charge in Q2 2026
  • Net leverage increased to 2.4x from 1.9x YoY despite debt reduction, due to lower trailing EBITDA

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001367644-26-000110
Document: ebs2026-09x30deckfinal.htm0001367644-26-000110
Document: ebs-20261102.htm0001367644-26-000110
Document: 0001367644-26-000110-index-headers.html0001367644-26-000110
Document: 0001367644-26-000110-index.html0001367644-26-000110
Document: 0001367644-26-000110.txt0001367644-26-000110
8-K Data (Synthetic)0001367644-26-000110

Track record

23 reports on EBS

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +14.89% at T+20 after the Apr 29, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
  4. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
  5. Nov 2, 202614d ago 8-K Bearish 6/10 Viewing Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
  6. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
  7. Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
  8. Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
  9. Jun 29, 202620w ago 8-K Bullish 5/10 Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
  10. Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026